Apr 22 |
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
|
Apr 18 |
Stifel starts Mirum at buy, cites IBATi drug potential
|
Apr 2 |
Mirum’s LIVMARLI receives positive reimbursement recommendation by Canada’s CADTH
|
Apr 2 |
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
|
Mar 29 |
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
|
Mar 28 |
$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying
|
Mar 26 |
Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares
|
Mar 25 |
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
|
Mar 15 |
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
|
Mar 14 |
Mirum gains as FDA accepts label expansion of liver disease drug
|